🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 13 of 757 · Phase 3 first, then by program name

  1. Afinitor 10 mg tablets, Aromasin 25 mg coated tablets, Faslodex 250 mg solution for injection., Afinitor 5 mg tablets

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Hormone receptor-positive, her2-negative advanced/metastatic breast cancer

    phase 3 small molecule active

    1 trial

  2. Afinitor 2.5 mg tablets, Afinitor 10 mg tablets

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Children, adolescents and adults with newly diagnosed diffuse intrinsic pontine glioma and other diffuse midline gliomas H3K28M mutant or EZHIP positive

    phase 3 small molecule active

    1 trial

  3. Afinitor 5 mg tablets, PLACEBO

    Cancer Prevention Pharma (Ireland) Limited

    Patients with high risk of relapse, ER+ and HER2- primary non-metastatic breast cancer who remain disease-free

    phase 3 small molecule active

    1 trial

  4. Aflibercept

    Regeneron UK Limited

    Colorectal Cancer Metastatic

    phase 3 small molecule completed

    3 trials

  5. Aflibercept

    Regeneron UK Limited

    Prostatic Neoplasms

    phase 3 small molecule completed

    1 trial

  6. Aflibercept (EYLEA, BAY86-5321)

    Regeneron UK Limited

    Glaucoma, Neovascular

    phase 3 small molecule completed

    1 trial

  7. Aflibercept (Eylea, BAY 86-5321)

    Regeneron UK Limited

    Glaucoma, Neovascular

    phase 3 small molecule completed

    1 trial

  8. Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Macular Edema

    phase 3 mab completed

    1 trial

  9. Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Macular Degeneration

    phase 3 mab completed

    1 trial

  10. Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

    Regeneron UK Limited

    Carcinoma

    phase 3 small molecule completed

    1 trial

  11. Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

    Regeneron UK Limited

    Pancreatic Neoplasm

    phase 3 small molecule terminated

    1 trial

  12. Aflibercept 8 mg

    Regeneron UK Limited

    Neovascular Age-Related Macular Degeneration

    phase 3 small molecule active

    1 trial

  13. Aflibercept AVE0005

    Regeneron UK Limited

    Colorectal Cancer Metastatic

    phase 3 small molecule terminated

    2 trials

  14. Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)

    Regeneron UK Limited

    Neovascular Age-Related Macular Degeneration

    phase 3 small molecule completed

    1 trial

  15. Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Retinal Vein Occlusion

    phase 3 mab completed

    1 trial

  16. Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose

    Regeneron UK Limited

    Macular Edema Secondary to Retinal Vein Occlusion

    phase 3 small molecule completed

    1 trial

  17. Agitated Saline SoC

    BRIGHT MINDS BIOSCIENCES INC.

    Right-To-Left Shunt

    phase 3 small molecule active

    1 trial

  18. Aglatimagene besadenovec + valacyclovir

    Candel Therapeutics

    Prostate Cancer

    phase 3 mab active

    1 trial

  19. Albendazole

    United Therapeutics Europe Ltd

    Helminthiasis

    phase 3 small molecule completed

    1 trial

  20. Albendazole (400 mg) and/or Vitamin a

    United Therapeutics Europe Ltd

    Malnutrition

    phase 3 small molecule completed

    1 trial

  21. Albutein 50 g/l solución para perfusión.

    Instituto Grifols S.A.

    Subjects with cirrhosis with ACLF-1b, ACLF-2, or ACLF-3a detected either at admission or during hospitalization

    phase 3 small molecule active

    1 trial

  22. Albuterol

    Teva Pharma GmbH

    Asthma

    phase 3 small molecule completed

    2 trials

  23. Albuterol MDPI

    Teva Pharma GmbH

    Asthma

    phase 3 small molecule completed

    1 trial

  24. Albuterol Spiromax

    Teva Pharma GmbH

    Exercise-Induced Bronchoconstriction (EIB)

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources